Cargando…

Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection

Exebacase (CF-301) is a novel antistaphylococcal lysin (cell wall hydrolase) in phase 3 of clinical development for the treatment of Staphylococcus aureus bacteremia, including right-sided endocarditis, used in addition to standard-of-care antibiotics. In the current study, the potential for exebaca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swift, Steven M., Sauve, Karen, Cassino, Cara, Schuch, Raymond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370210/ https://www.ncbi.nlm.nih.gov/pubmed/34228536 http://dx.doi.org/10.1128/AAC.02723-20

Ejemplares similares

Rapid bacteriolysis of Staphylococcus aureus by lysin exebacase
por: Vila-Farres, Xavier, et al.
Publicado: (2023)

In vitro activity of exebacase against methicillin-resistant Staphylococcus aureus biofilms on orthopedic Kirschner wires
por: Karau, Melissa J., et al.
Publicado: (2023)

711. Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)
por: Anastasiou, Diane, et al.
Publicado: (2019)

671. Impact of Dose-Administration Strategies of the Antistaphylococcal Lysin Exebacase, (CF-301), in Addition to Daptomycin (DAP) in an Experimental Infective Endocarditis (IE) Model due to Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Xiong, Yan, et al.
Publicado: (2019)

Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis
por: Karau, Melissa, et al.
Publicado: (2022)

712. Activity of Exebacase (CF-301) Against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms on Orthopedic Kirschner Wires
por: Karau, Melissa J, et al.
Publicado: (2019)

Development of a Broth Microdilution Method for Exebacase Susceptibility Testing
por: Oh, Jun T., et al.
Publicado: (2021)

Lysin CF-301 Demonstrates In Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus
por: Sauve, Karen, et al.
Publicado: (2017)

Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections
por: Souche, Aubin, et al.
Publicado: (2022)

LB12. Exebacase Shows Rapid Symptom Resolution in a Phase 2 Study in Adult Patients with Staphylococcus aureus bacteremia
por: Cassino, Cara, et al.
Publicado: (2021)

1342. Comparison of Lysin CF-301 (Exebacase) Activity Against S. aureus Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates
por: Anastasiou, Diane, et al.
Publicado: (2018)

1324. Target Attainment of Exebacase, a First-In-Class Antibacterial Lysin, to Determine Optimal Doses for Adult Patients with Staphylococcus aureus (S. aureus) Bloodstream Infections (Bacteremia) Including Endocarditis
por: Ghahramani, Parviz, et al.
Publicado: (2020)

LB3. Exebacase (EXE) Reduced Length of Stay and 30-Day Readmission Rates for US Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia Including Endocarditis Compared with Standard of Care Antibiotics (SoC) Alone in a Phase 2 Study
por: Cassino, Cara, et al.
Publicado: (2019)

The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics
por: Oh, Jun, et al.
Publicado: (2023)

1264. Assessment of In Vivo Efficacy of CF-296 in addition to Vancomycin (VAN) and Daptomycin (DAP) against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model
por: Asempa, Tomefa E, et al.
Publicado: (2020)

Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Geriak, Matthew, et al.
Publicado: (2019)

1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models
por: Ghahramani, Parviz, et al.
Publicado: (2019)

Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii
por: Sakoulas, George, et al.
Publicado: (2017)

1059. In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-resistant Subsets
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a Systematic Review and Meta-analysis
por: Wang, Chunjiang, et al.
Publicado: (2020)

Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity
por: Traczewski, Maria M., et al.
Publicado: (2021)

Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia
por: Sakoulas, George, et al.
Publicado: (2016)

Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial
por: Pujol, Miquel, et al.
Publicado: (2020)

Daptomycin-Nonsusceptible Staphylococcus aureus: The Role of Combination Therapy with Daptomycin and Gentamicin
por: Jiang, Jhih-Hang, et al.
Publicado: (2015)

1539. Dalbavancin, Vancomycin, and Daptomycin Alone and in Combination with Cefazolin Against Vancomycin Intermediate-Resistant (VISA) and Daptomycin Non-Susceptible (DNS) Staphylococcus aureus
por: Abdul-Mutakabbir, Jacinda, et al.
Publicado: (2019)

Catalase Protects Biofilm of Staphylococcus aureus against Daptomycin Activity
por: El Haj, Cristina, et al.
Publicado: (2021)

Daptomycin in treatment of Methicillin-resistant Staphylococcus aureus diskitis
por: Parlato, Ciro, et al.
Publicado: (2011)

Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections
por: Nadrah, Kristina, et al.
Publicado: (2011)

Daptomycin susceptibility of methicillin resistant Staphylococcus aureus (MRSA)
por: Kaur, Rajneet, et al.
Publicado: (2012)

117. Adjunctive Daptomycin in the Treatment of staphylococcus Aureus Bacteremia
por: Cheng, Matthew P, et al.
Publicado: (2020)

Fitness Cost of Daptomycin-Resistant Staphylococcus aureus Obtained from in Vitro Daptomycin Selection Pressure
por: Li, Shuguang, et al.
Publicado: (2017)

Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2020)

Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus
por: Hagihara, Mao, et al.
Publicado: (2012)

Characterization of genetic changes associated with daptomycin nonsusceptibility in Staphylococcus aureus
por: Ma, Zhuo, et al.
Publicado: (2018)

Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis
por: Karau, Melissa J., et al.
Publicado: (2022)

Genomic and Long-Term Transcriptomic Imprints Related to the Daptomycin Mechanism of Action Occurring in Daptomycin- and Methicillin-Resistant Staphylococcus aureus Under Daptomycin Exposure
por: Cafiso, Viviana, et al.
Publicado: (2020)

Combination Therapy With Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus–Induced Murine Bacteremia
por: Schuch, Raymond, et al.
Publicado: (2014)

Evaluation of Daptomycin Non-Susceptible Staphylococcus aureus for Stability, Population Profiles, mprF Mutations, and Daptomycin Activity
por: Steed, Molly E., et al.
Publicado: (2013)

Glucose Augments Killing Efficiency of Daptomycin Challenged Staphylococcus aureus Persisters
por: Prax, Marcel, et al.
Publicado: (2016)

The Role of Subinhibitory Concentrations of Daptomycin and Tigecycline in Modulating Virulence in Staphylococcus aureus
por: Atshan, Salman Sahab, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c35emb8311854oclufg89o06p2